ARREST Trial: Precision Radiation Boosts to Fix 177Lu-PSMA’s 50% Failure Rate

ARREST trial could change mCRPC treatment by solving 177Lu-PSMA’s biggest limitation: up to 50% of patients get little benefit despite FDA approval and proven survival gains. The simple idea? Add targeted external beam radiation boosts to the tumors that radioligand therapy misses, creating a hybrid approach that could cut skeletal complications dramatically.

Current 177Lu-PSMA therapy works well on average, but the problem lies in uneven tumor killing. Some metastatic lesions simply don’t absorb enough radiation from the systemic radioligand, leaving dangerous “cold spots” that continue growing and causing bone fractures, spinal cord compression, and severe pain. Half of mCRPC patients face these skeletal disasters within two years, even with best-available therapy.

The ARREST solution attacks this head-on with smart lesion selection. They don’t blast every metastasis, but just the troublemakers identified by three key signals:

• Tumors getting too little radiation dose from 177Lu-PSMA (measured by SPECT-CT scans)
• “Discordant” lesions lighting up on aggressive-cancer FDG-PET but dim on PSMA scans
• Symptomatic spots or bones at high fracture risk

A single, high-precision radiation fraction (6-12 Gy in under 60 minutes) hits these targets precisely, aiming for a combined biological dose that obliterates resistant cancer cells. Preclinical data proves the synergy: mouse studies showed 60% survival extension versus radiation alone, with tumors growing 2.7 times slower.

Why this combination makes biological sense: external beam radiation temporarily supercharges PSMA expression on cancer cells(18% protein increase within hours, 2.6-fold mRNA spike). This creates a perfect setup where subsequent radioligand doses hit harder. The single-fraction approach mirrors proven bone metastasis pain relief strategies, where one big dose outperforms weeks of conventional radiation.

Safety looks promising from early combination data, as no excess severe toxicity in small retrospective series. The main concerns (bone marrow suppression, kidney strain) follow known 177Lu-PSMA patterns that mostly reverse within 4-6 weeks. ARREST’s adaptive design even pauses treatment for complete responders, avoiding overtreatment.

Clinical trial.